Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
3.8300
+0.00 (0.00%)
NASDAQ · Last Trade: Feb 26th, 9:43 AM EST
Detailed Quote
Previous Close
3.830
Open
-
Bid
3.790
Ask
3.820
Day's Range
N/A - N/A
52 Week Range
1.639 - 5.640
Volume
311,258
Market Cap
1.17B
PE Ratio (TTM)
-3.514
EPS (TTM)
-1.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
14,282,694
Chart
About Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapy products for the treatment of cancer. The company specializes in the use of tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the body’s immune system to target and destroy cancer cells. By processing and expanding patients' own immune cells, Iovance aims to create personalized therapies that can provide effective options for those with various types of solid tumors. Their innovative approach leverages advancements in cell therapy to improve patient outcomes and contribute to the evolving landscape of cancer treatment. Read More
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance’s common stock to two new, non-executive employees.
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates.
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,710 shares of Iovance’s common stock to 17 new, non-executive employees.
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of
SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 43,150 shares of Iovance’s common stock to four new, non-executive employees.
BioMedWire Editorial Coverage : As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (“GAAP”) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( profile ) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (“JV”) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic Therapeutics’ position as a treatment leader, along with others in the oncology-treatment space, including Iovance Biotherapeutics Inc . (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and…
SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 164,900 shares of Iovance’s common stock to 11 new, non-executive employees.
AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (JV) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic Therapeutics’ position as a treatment leader, along with others in the oncology-treatment space, including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ).
